Previous 10 | Next 10 |
SAN DIEGO and CAMBRIDGE, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR) today announced the publication of interim results from the Phase 1b trial of VY-AADC, an investigational gene therapy treatment for P...
Thermo Fisher Scientific Inc. ( TMO ) made a bold strategic move to acquire a gene therapy manufacturer known as Brammer Bio . This was done to get some type of position into the ever-growing gene therapy space. The sector is starting to expand with additional new biotechs seeking to explore ...
Since my earlier article , Neurocrine Biosciences ( NBIX ) shares have retreated quite a bit off all time highs in September 2018. The safety scare was the first major selloff on elevated volume as an increase in reported deaths caused a panic, sending shares down over 10% one day in November...
MRI Interventions ( OTCQB:MRIC ) collaborates with Voyager Therapeutics (NASDAQ: VYGR ) to design, manufacture and supply the Variable Trajectory Array Guide, or V-TAG, neurosurgical device for Voyager. More news on: MRI Interventions, Inc., Voyager Therapeutics, Inc., Healthcare stocks ...
IRVINE, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCQB:MRIC) a platform neurosurgery company developing products designed to deliver navigation, ablation, deep brain stimulation, aspiration, biopsy and gene therapy today announced a collaboration with Voyager Ther...
Voyager Therapeutics (NASDAQ: VYGR ) initiated with Overweight rating and $27 (52% upside) price target at Cantor Fitzgerald. More news on: Voyager Therapeutics, Mylan Inc, Teva Pharmaceutical Industries Limited, Healthcare stocks news, Stocks on the move, , Read more ...
The following slide deck was published by Voyager Therapeutics in conjunction with this Read more ...
Neurocrine Moves Into Gene Therapy Introduction Staying true to their pipeline targeting movement disorders, Neurocrine Biosciences ( NBIX ) nabbed a deal with Voyager Therapeutics ( VYGR ) for the development and commercialization rights to gene therapy programs VY-AADC for Parki...
Voyager Therapeutics (VYGR) Q4 2018 Results Earnings Conference Call February 26, 2019, 04:30 PM ET Company Participants Matt Osborne - Vice President-Corporate Affairs, Communications and Investor Relations Andre Turenne - President and Chief Executive Officer Allison Dorval - C...
Recently, Voyager Therapeutics ( VYGR ) announced that it had generated a partnership with AbbVie ( ABBV ) for Parkinson's disease and other neurodegenerative diseases. This deal is expected to be worth up to >$1 billion. I believe that Voyager will greatly benefit from having such a st...
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, ...
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgense...
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigation...